China forces R&D access in Danaher/GE biopharma deal
Credit: Shutterstock/Casimiro PT
Danaher must provide research and development resources for an unfinished project related to the separation and purification of biomolecules as a condition for buying GE’s biopharma business, China’s competition watchdog has decided.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now